Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 1161 |
| INN | None |
| Status | Clinical |
| Drug code(s) | QX002N |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | TBD |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | IL-17A |
| Indications of clinical studies | Ankylosing spondylitis |
| Primary therapeutic area | Immune-mediated / inflammatory disorders |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | November 15, 2019 |
| Start of Phase 2 | September 15, 2021 |
| Start of Phase 3 | September 15, 2023 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Jiangsu Qyuns Therapeutics Co. Ltd. |
| Licensee/Partner | None |
| Comments about company or candidate | CTR20232574 Phase 3 in active ankylosing spondylitis started in Sep 2024. Phase 1 study identifier ChiCTR1900023040. |
| Full address of company | No.907 Yaocheng Avenue, Taizhou, Jiangsu, China Asia China https://www.qyuns.net/en/ |
QX002N, an innovative first-in-class biological product, is a high affinity recombinant humanized IgG1 monoclonal antibody against human IL-17A. QX002N was produced using Chinese hamster ovary cells and supplied by Qyuns Therapeutics Co., Ltd. (Taizhou, Jiangsu, China). https://www.frontiersin.org/articles/10.3389/fphar.2021.794054/full
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |